Healthcare · Medical - Care Facilities
Price
$23.24
Market Cap
$12.5B
Employees
112,035
Beta
0.81
Avg Volume
708,200
CEO
Helen Giza
Business Description
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
APIStock Price / EPS (Diluted)
11.90
Stock Price: $23.24
EPS (Diluted): 1.68
EPS (Diluted): 1.68
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.83
Stock Price: $23.24
Total Equity: $14.28B
Shares: 582,381,150
Total Equity: $14.28B
Shares: 582,381,150
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
5.99
Market Cap: $12.48B
Total Debt: $7.31B
Cash: $1.60B
EBITDA: $3.40B
Total Debt: $7.31B
Cash: $1.60B
EBITDA: $3.40B
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$21.0B
Market Cap: $12.48B
Total Debt: $7.31B
Cash: $1.60B
Total Debt: $7.31B
Cash: $1.60B
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
25.6%
Gross Profit: $5.03B
Revenue: $19.63B
Revenue: $19.63B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
9.3%
Operating Income: $1.83B
Revenue: $19.63B
Revenue: $19.63B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
5.0%
Net Income: $978.37M
Revenue: $19.63B
Revenue: $19.63B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
7.2%
Net Income: $978.37M
Total Equity: $14.28B
Total Equity: $14.28B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
5.8%
Operating Income: $1.83B
Tax Rate: 21.2%
Equity: $14.28B
Total Debt: $7.31B
Cash: $1.60B
Tax Rate: 21.2%
Equity: $14.28B
Total Debt: $7.31B
Cash: $1.60B
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.26
Current Assets: $7.90B
Current Liabilities: $6.25B
Current Liabilities: $6.25B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.51
Short-Term Debt: $1.61B
Long-Term Debt: $5.69B
Total Debt: $7.31B
Total Equity: $14.28B
Long-Term Debt: $5.69B
Total Debt: $7.31B
Total Equity: $14.28B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$33.70
Revenue: $19.63B
Shares: 582,381,150
Shares: 582,381,150
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$24.53
Total Equity: $14.28B
Shares: 582,381,150
Shares: 582,381,150
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$2.91
Operating CF: $2.58B
CapEx: -$879.24M
Shares: 582,381,150
CapEx: -$879.24M
Shares: 582,381,150
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
3.4%
Last Dividend: N/A
Stock Price: $23.24
Stock Price: $23.24
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $978.37M
Net Income: $978.37M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares FMS against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:04pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.6B | $19.4B | $19.5B | $19.3B | $19.6B |
| Cost of Revenue | $12.8B | $14.5B | $14.5B | $14.6B | $14.6B |
| Gross Profit | $4.8B | $4.9B | $4.9B | $4.8B | $5.0B |
| Operating Expenses | $2.9B | $3.4B | $3.6B | $3.3B | $3.2B |
| Operating Income | $1.9B | $1.5B | $1.4B | $1.5B | $1.8B |
| Net Income | $969.3M | $673.4M | $499.0M | $537.9M | $978.4M |
| EBITDA | $3.5B | $3.4B | $3.2B | $3.2B | $3.4B |
| EPS | $0.83 | $0.57 | $0.85 | $0.92 | $1.68 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:04pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.5B | $1.3B | $1.4B | $1.2B | $1.6B |
| Total Current Assets | $8.0B | $8.2B | $8.7B | $7.9B | $7.9B |
| Total Assets | $34.4B | $35.8B | $33.9B | $33.6B | $31.0B |
| Current Liabilities | $7.3B | $6.5B | $6.1B | $5.7B | $6.2B |
| Long-Term Debt | $6.6B | $7.2B | $7.0B | $6.3B | $5.7B |
| Total Liabilities | $20.4B | $20.3B | $19.1B | $17.8B | $16.7B |
| Total Equity | $12.7B | $14.0B | $13.6B | $14.6B | $14.3B |
| Retained Earnings | $10.8B | $10.7B | $10.9B | $11.3B | $0 |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:04pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.5B | $2.2B | $2.6B | $2.4B | $2.6B |
| Capital Expenditure | -$854.4M | -$724.0M | -$684.6M | -$699.4M | -$879.2M |
| Free Cash Flow | $1.6B | $1.4B | $1.9B | $1.7B | $1.7B |
| Acquisitions (net) | -$381.7M | $1.0M | $137.0M | $606.7M | $223.3M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$562.2M |
| Net Change in Cash | $400.1M | -$207.9M | $153.4M | -$241.9M | $558.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 6:15am (2h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$20.5B $20.3B – $20.8B
|
$21.3B $21.0B – $22.2B
|
$22.4B $22.0B – $23.3B
|
$23.3B $23.0B – $24.3B
|
| EBITDA |
$3.6B $3.6B – $3.7B
|
$3.8B $3.7B – $3.9B
|
$3.9B $3.9B – $4.1B
|
$4.1B $4.1B – $4.3B
|
| Net Income |
$1.3B $1.2B – $1.4B
|
$1.5B $1.4B – $1.5B
|
$1.7B $1.7B – $1.8B
|
$1.9B $1.9B – $2.0B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:04pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +10.1% | +0.3% | -0.6% | +1.5% |
| Gross Profit Growth | +2.5% | +0.6% | -3.4% | +5.7% |
| Operating Income Growth | -18.4% | -9.4% | +7.2% | +24.5% |
| Net Income Growth | -30.5% | -25.9% | +7.8% | +81.9% |
| EBITDA Growth | -3.7% | -6.1% | -0.1% | +6.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:15am (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-18 | Renkewitsch Olga | 0.00 | $0.00 | $0 |
Dividend History (Last 20)
Last updated: Jun 21, 2026 7:04pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-05-22 | $0.86 | 2026-05-01 | 2026-05-22 | 2026-06-08 |
| 2025-05-23 | $0.81 | 2025-05-07 | 2025-05-23 | 2025-06-06 |
| 2024-05-17 | $0.63 | 2024-04-15 | 2024-05-20 | 2024-06-03 |
| 2023-05-17 | $0.62 | 2023-05-03 | 2023-05-18 | 2023-06-01 |
| 2022-05-13 | $0.71 | 2022-04-28 | 2022-05-16 | 2022-05-27 |
| 2021-05-24 | $0.83 | 2021-05-17 | 2021-05-25 | 2021-06-07 |
| 2020-08-28 | $0.71 | 2020-08-12 | 2020-08-31 | 2020-09-11 |
| 2019-05-17 | $0.66 | 2019-05-08 | 2019-05-20 | 2019-05-31 |
| 2018-05-21 | $0.63 | 2018-05-10 | 2018-05-22 | 2018-06-04 |
| 2017-05-11 | $0.51 | 2017-04-24 | 2017-05-15 | 2017-05-26 |
| 2016-05-10 | $0.44 | 2016-03-09 | 2016-05-12 | 2016-05-23 |
| 2015-05-15 | $0.44 | 2015-06-01 | ||
| 2014-05-13 | $0.53 | 2014-05-02 | 2014-05-15 | 2014-05-27 |
| 2013-05-14 | $0.49 | 2013-05-14 | 2013-05-16 | 2013-05-28 |
| 2012-05-08 | $0.91 | 2012-05-21 | ||
| 2011-05-10 | $0.95 | 2011-05-23 | ||
| 2010-05-07 | $0.82 | |||
| 2009-05-05 | $0.75 | |||
| 2008-05-16 | $0.83 | |||
| 2007-05-11 | $0.63 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for FMS — it's generated by the pipeline (
market-narrative step).
No community reviews yet for FMS.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30